Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort

IntroductionSince current studies on locally advanced pancreatic cancer (LAPC) mainly report from single, high-volume centers, it is unclear if outcomes can be translated to daily clinical practice. This study provides treatment strategies and within a multicenter cohort of unselected patients with LAPC.Materials methodsConsecutive LAPC according Dutch Pancreatic Cancer Group criteria, were prospectively included in 14 centers April 2015 until December 2017. A centralized expert panel reviewed response RECIST v1.1 potential surgical resectability. Primary outcome was median overall survival (mOS), stratified for primary strategy.ResultsOverall, 422 included, whom 77% (n = 326) received chemotherapy. The majority started FOLFIRINOX (77%, 252/326) six cycles (IQR 4–10). Gemcitabine monotherapy given 13% (41/326) nab-paclitaxel/gemcitabine 10% (33/326), two 3–5) three respectively. mOS the entire 10 months (95%CI 9–11). In treated FOLFIRINOX, gemcitabine monotherapy, or nab-paclitaxel/gemcitabine, 13–15), 9 8–10), resection performed (32/252) after resulting 23 12–34).ConclusionThis resulted month rate FOLFIRINOX. These data put previous results perspective, enable us inform more accurate numbers will support decision-making